Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
Isatuximab SAR650984
Cemiplimab REGN2810
Locations
30
United States
University of Colorado-Site Number:8400001
Denver, Colorado, United States
University of Kansas Medical Center-Site Number:8400003
Kansas City, Kansas, United States
Memorial Sloan-Kettering Cancer Center-Site Number:8400002
New York, New York, United States
Fox Chase Cancer Center-Site Number:8400004
Philadelphia, Pennsylvania, United States
Investigational Site Number :0360003
Wollongong, New South Wales, Australia
Investigational Site Number :0360002
Richmond, Victoria, Australia
Start Date
February 21, 2018
Primary Completion Date
April 5, 2023
Completion Date
April 5, 2023
Last Updated
June 14, 2024
NCT06356571
NCT05334069
NCT05312255
NCT04508790
NCT04876248
NCT04640779
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions